英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Endo - Home | Introducing Keenova and Par Health
    On July 31, 2025, Mallinckrodt and Endo joined together to better serve patients and customers with a bold plan for the future Following the merger, the combined company then spun off its generics and sterile injectables business as an independent company—Par Health—and rebranded the specialty therapeutics company as Keenova Therapeutics in November 2025
  • Investors | Endo - Press Releases
    Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader - Highly Complementary Companies to Advance Therapies to Address Unmet Patient Needs - Respective Generics Businesses and Endo's Sterile Injectables Business to be Combined and Spun Off as an Independent Company with Target Date in the Fourth Quarter of
  • Investors | Endo - Overview
    Endo’s board of directors oversees and advises our leaders to protect the long-term interests of the company and our shareholders The experienced and independent board members are committed to building sustainable success
  • Mallinckrodt and Endo to Combine to Create a Global, Scaled . . .
    About Endo Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies Our passionate team members collaborate to develop and deliver these essential medicines Together, we are committed to helping everyone we serve live their best life Learn more at www endo com or connect with us on LinkedIn
  • Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
    Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, 2025
  • Endo Investor Relations - SEC Filings
    Investors Overview Press Releases Board Committees Board Policies Guidelines Events Presentations Financial Information SEC Filings FAQs Company Purpose Leadership History Policies Statements Contact Locations Products Capabilities Focus Areas Products Manufacturing Suppliers Research Development R D Approach Pipeline Clinical Research Grants Newsroom Media Stories Responsibility
  • Endo Reports Fourth-Quarter and Full-Year 2024 Financial Results
    Endo achieved 2024 revenues and adjusted EBITDA expectations, while progressing the Company's strategic priorities XIAFLEX® hit record revenues of $516 million in 2024, up 9% versus 2023 The Company provides 2025 revenue guidance of $1,775 to $1,860 million and adjusted EBITDA guidance of $620 to $650 million MALVERN, Pa , March 13, 2025 PRNewswire -- Endo, Inc ("Endo" or the "Company
  • Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with Three New . . .
    Endo now offers ADRENALIN® premixed IV bags in five of the most used concentrations, including the 5 mg and 10 mg which align with ASHP's Standardize 4 Safety Initiative Endo's products are the first FDA-approved, commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag
  • Endo Reports First-Quarter 2025 Financial Results and Reaffirms 2025 . . .
    FINANCIAL GUIDANCE Based on first-quarter 2025 results, Endo is reaffirming its previously provided financial guidance for the full year ending December 31, 2025 Guidance for the full year 2025 is based on Endo's current views, beliefs, estimates and assumptions
  • Endo Pharmaceuticals, Inc. - Sign In
    Secure access to Endo International's resources and services through this portal





中文字典-英文字典  2005-2009